Pioglitazone did not reduce macrovascular complications and increased HF in type 2 diabetes with macrovascular diseaseSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study PROspective pioglitAzone Clinical Trial In macroVascular Events: a randomised controlled trial.

Isley, William L MD (commentator)
Dormandy, JA
Charbonnel, B
Eckland, DJ
et al,

Mayo Clinic, Rochester, Minnesota, USA

Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279–89.DormandyJACharbonnelBEcklandDJet alSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study PROspective pioglitAzone Clinical Trial In macroVascular Events: a randomised controlled trial.Lancet20053661279-89Q In patients with type 2 diabetes and evidence of macrovascular disease, does pioglitazone reduce all cause mortality and macrovascular complications?

For correspondence: Dr J A Dormandy, St. George’s Hospital, UK. [email protected]

Sources of funding: Takeda Pharmaceutical Company and Eli Lily and Company.

Evidence Based Medicine 11(2):p 47, April 2006.

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★★☆ Cardiology ★★★★★★☆